08:17 AM EDT, 06/12/2024 (MT Newswires) -- Dianthus Therapeutics ( DNTH ) said Wednesday that the US Food and Drug Administration has approved an Investigational New Drug application for the launch of its phase 2 trial assessing the efficacy, safety, and tolerability of DNTH103 in 36 patients with multifocal motor neuropathy.

Preliminary top-line results will likely be available in H2 2026, said the company, which is looking to achieve the primary endpoint of safety and tolerability along with secondary endpoints that include time to relapse and assessments of muscle and grip strength.